• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MBI extends Mallinckrodt's FS069 rights

Article

Molecular Biosystems of San Diego has extended Mallinckrodt Medical'srights to its FS069 ultrasound contrast agent to Europe, Russia,Africa, and India. In exchange for the new rights, Mallinckrodtof St. Louis will pay MBI fees of up to $12.9 million,

Molecular Biosystems of San Diego has extended Mallinckrodt Medical's

rights to its FS069 ultrasound contrast agent to Europe, Russia,

Africa, and India. In exchange for the new rights, Mallinckrodt

of St. Louis will pay MBI fees of up to $12.9 million, plus 40%

of product sales for royalties and manufacturing. The companies

filed a premarket approval application for U.S. marketing of FS069,

a second-generation contrast agent, earlier this year. They plan

to file for European approval in early 1997.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.